Stock Track | Pediatrix Medical Soars 11.59% Pre-Market on Strong Q3 Results and Raised Outlook

Stock Track

Nov 03, 2025

Pediatrix Medical Group (NYSE:MD) saw its stock surge 11.59% in pre-market trading on Monday following the release of its impressive third-quarter results and an upward revision of its full-year outlook. The healthcare services provider reported better-than-expected earnings and revenue, demonstrating resilience in a challenging healthcare environment.

The company reported third-quarter adjusted earnings of $0.67 per share, significantly surpassing the analyst consensus estimate of $0.47. This represents a 52.27% increase from the $0.44 per share reported in the same period last year. Quarterly revenue came in at $492.875 million, beating the analyst estimate of $476.493 million by 3.44%. Although this figure represents a 3.58% decrease from the previous year's $511.158 million, it still impressed investors given the current market conditions.

Pediatrix Medical's strong performance was attributed to improved collection activity, higher patient acuity, and a favorable payor mix. The company's CEO, Mark S. Ordan, highlighted these factors as key drivers of the quarter's success. Additionally, Pediatrix raised its full-year 2025 Adjusted EBITDA outlook to a range of $270 million to $290 million, up from the previous estimate of $245 million to $255 million. This upward revision further fueled investor optimism, contributing to the stock's pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121310919"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121310919\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121310919?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121310919","market":"hk","top_or_hot":-1,"title":"Stock Track | Pediatrix Medical Soars 11.59% Pre-Market on Strong Q3 Results and Raised Outlook","media":"Stock Track","content":"<p>Pediatrix Medical Group (NYSE:MD) saw its stock surge 11.59% in pre-market trading on Monday following the release of its impressive third-quarter results and an upward revision of its full-year outlook. The healthcare services provider reported better-than-expected earnings and revenue, demonstrating resilience in a challenging healthcare environment.</p>\n\n<p>The company reported third-quarter adjusted earnings of $0.67 per share, significantly surpassing the analyst consensus estimate of $0.47. This represents a 52.27% increase from the $0.44 per share reported in the same period last year. Quarterly revenue came in at $492.875 million, beating the analyst estimate of $476.493 million by 3.44%. Although this figure represents a 3.58% decrease from the previous year's $511.158 million, it still impressed investors given the current market conditions.</p>\n\n<p>Pediatrix Medical's strong performance was attributed to improved collection activity, higher patient acuity, and a favorable payor mix. The company's CEO, Mark S. Ordan, highlighted these factors as key drivers of the quarter's success. Additionally, Pediatrix raised its full-year 2025 Adjusted EBITDA outlook to a range of $270 million to $290 million, up from the previous estimate of $245 million to $255 million. This upward revision further fueled investor optimism, contributing to the stock's pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pediatrix Medical Soars 11.59% Pre-Market on Strong Q3 Results and Raised Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pediatrix Medical Soars 11.59% Pre-Market on Strong Q3 Results and Raised Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-03 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pediatrix Medical Group (NYSE:MD) saw its stock surge 11.59% in pre-market trading on Monday following the release of its impressive third-quarter results and an upward revision of its full-year outlook. The healthcare services provider reported better-than-expected earnings and revenue, demonstrating resilience in a challenging healthcare environment.</p>\n\n<p>The company reported third-quarter adjusted earnings of $0.67 per share, significantly surpassing the analyst consensus estimate of $0.47. This represents a 52.27% increase from the $0.44 per share reported in the same period last year. Quarterly revenue came in at $492.875 million, beating the analyst estimate of $476.493 million by 3.44%. Although this figure represents a 3.58% decrease from the previous year's $511.158 million, it still impressed investors given the current market conditions.</p>\n\n<p>Pediatrix Medical's strong performance was attributed to improved collection activity, higher patient acuity, and a favorable payor mix. The company's CEO, Mark S. Ordan, highlighted these factors as key drivers of the quarter's success. Additionally, Pediatrix raised its full-year 2025 Adjusted EBITDA outlook to a range of $270 million to $290 million, up from the previous estimate of $245 million to $255 million. This upward revision further fueled investor optimism, contributing to the stock's pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MD","symbol_name":"Pediatrix Medical","start_time":0,"source_url":"","article_id":"1121310919","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121310919","pubTimestamp":1762174947,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Pediatrix Medical Group (NYSE:MD) saw its stock surge 11.59% in pre-market trading on Monday following the release of its impressive third-quarter results and an upward revision of its full-year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MD":"Pediatrix Medical"},"translate_title":"个股追踪|Pediatrix Medical盘前大涨11.59%，Q3业绩强劲，展望上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MD":1},"content_text":"Pediatrix Medical Group (NYSE:MD) saw its stock surge 11.59% in pre-market trading on Monday following the release of its impressive third-quarter results and an upward revision of its full-year outlook. The healthcare services provider reported better-than-expected earnings and revenue, demonstrating resilience in a challenging healthcare environment.\nThe company reported third-quarter adjusted earnings of $0.67 per share, significantly surpassing the analyst consensus estimate of $0.47. This represents a 52.27% increase from the $0.44 per share reported in the same period last year. Quarterly revenue came in at $492.875 million, beating the analyst estimate of $476.493 million by 3.44%. Although this figure represents a 3.58% decrease from the previous year's $511.158 million, it still impressed investors given the current market conditions.\nPediatrix Medical's strong performance was attributed to improved collection activity, higher patient acuity, and a favorable payor mix. The company's CEO, Mark S. Ordan, highlighted these factors as key drivers of the quarter's success. Additionally, Pediatrix raised its full-year 2025 Adjusted EBITDA outlook to a range of $270 million to $290 million, up from the previous estimate of $245 million to $255 million. This upward revision further fueled investor optimism, contributing to the stock's pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}